

Dear Lian-Sheng Ma,

We appreciate your helpful comments and those of the reviewers. We feel that the manuscript is now greatly improved. Revisions based on the comments/suggestions of Reviewers #1, 2, 3 and 4 were made. The comments of each reviewer are numbered below, followed by a response indicating the modifications made.

Reviewer #1: Comments: 1. It is a mini review, the whole paper size is too big, be better emphasize the recent progresses. 2. In the last paragraph, the author didn't give a clear conclusion regarding the management of liver hemangioma, especially the trend of reflecting minimal invasive or non-surgical therapy, including the opinions of the author himself. 3. The references are too many be better less than 50.

- Thank you for your revision and suggestions, we think they improved our review substantially. 1. We tried to emphasize the relevant concepts of hepatic hemangioma and recent progresses, other reviewers comments suggested including recent research targeting new pathways for possible therapies which has been included. 2. The conclusion has been modified reflecting the trend of minimal invasive and non-surgical therapy. 3. Regarding the references, all citations were reviewed and information in the article is properly cited from the data abstraction source.

Reviewer #2: Comments: A concise, but objective and well written revision on hepatic hemangioma. Although no personal experience of the authors is reported in the manuscript, the main clinical points were duly covered. It is recommended for publication.

- Thank you for your comments. We appreciate the insight provided to our paper.

Reviewer #3: Comments: 1. Major point in non-surgical management, the effect of anti-VEGF was referred, thus the authors should molecularly explain the pathogenesis of HH, such as mTORC1-VEGF pathway. 2. Minor point In abstract, the abbreviation is not appropriate. "Hepatic Hemangioma" should change "Hepatic Hemangioma (HH)" in the first line.

- Thank you for your revision and suggestions, we think they improved our review substantially. 1. The section of pathogenesis has been updated and anti-VEGF/mTORC1 pathway has been included. 2. The abstract has been corrected with the proper abbreviation.

Reviewer #4: Comments: 1. In the abstract, please explain the abbreviation HH in the first use. 2. There is a typo in the "Symptoms" section. 3. Please amend the following phrase to avoid generalization: "however symptoms present when a HH is larger than >5 cm"

- Thank you for your revision and suggestions, we think they improved our review substantially. 1. The abbreviation in the abstract has been explained. 2. The typo in "Symptoms" section has been corrected "distention". 3. We have changed the phrase "symptoms may present when a HH is large than >5 cm" and proper cited.